UK guidelines promise boost in genetics cascade screening (and early treatments)
This article was originally published in Scrip
Genetic testing guidelines published yesterday in the UK may significantly increase the use of genetic 'cascade' screening for familial predispositions. The guidelines address some of the obstacles to the extended use of genetic screening within families and conclude that, with appropriate safeguards, more genetic cascading will provide an overall cost-benefit to the UK’s health provider, the National Health Service.
You may also be interested in...
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.